Suzhou Medek Biopharma

Suzhou Medek Biopharma is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, dedicated to developing innovative small molecule therapeutics for metabolic and chronic diseases. The company's research and development efforts primarily target non-alcoholic steatohepatitis (NASH), obesity, and type 2 diabetes. Its lead candidate, MDK-001, is a highly selective thyroid hormone receptor beta (THR-beta) agonist designed to treat NASH by improving lipid metabolism and reducing liver fat. Medek Biopharma utilizes a proprietary drug discovery platform to identify molecules with optimized potency and selectivity. The company has successfully raised multiple rounds of financing from leading healthcare investors to advance its clinical pipeline.